替西帕单抗诱导难治性系统性红斑狼疮缓解 - Suppr

Suppr

超能文献

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.

作者信息

Alexander Tobias, Krönke Jan, Cheng Qingyu, Keller Ulrich, Krönke Gerhard

机构信息

Charité-Universitätsmedizin Berlin, Berlin, Germany.

出版信息

N Engl J Med. 2024 Sep 5;391(9):864-866. doi: 10.1056/NEJMc2407150.

DOI:10.1056/NEJMc2407150

PMID:39231352

Abstract

摘要

相似文献

Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.

N Engl J Med. 2024 Sep 5;391(9):864-866. doi: 10.1056/NEJMc2407150.

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.

Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.

Teclistamab in Relapsed or Refractory Multiple Myeloma.

N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.

Short-term add-on tocilizumab and intravenous cyclophosphamide exhibited a remission-inducing effect in a patient with systemic lupus erythematosus with refractory multiorgan involvements including massive pericarditis and glomerulonephritis.

Mod Rheumatol. 2017 May;27(3):529-532. doi: 10.3109/14397595.2014.990409. Epub 2014 Dec 30.

A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.

Int J Hematol. 2025 Feb;121(2):222-231. doi: 10.1007/s12185-024-03884-z. Epub 2024 Nov 28.

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512. doi: 10.1136/ard-2024-225686.

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.

Clin Pharmacokinet. 2018 Jun;57(6):717-728. doi: 10.1007/s40262-017-0586-5.

Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.

Expert Rev Hematol. 2024 Jun;17(6):197-200. doi: 10.1080/17474086.2024.2353751. Epub 2024 May 11.

BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.

N Engl J Med. 2024 Sep 5;391(9):867-869. doi: 10.1056/NEJMc2408786.

Interstitial granulomatous dermatitis associated with lupus: A case report.

Reumatol Clin. 2017 Nov-Dec;13(6):367-368. doi: 10.1016/j.reuma.2017.01.005. Epub 2017 Mar 27.

引用本文的文献

Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.

Nat Rev Rheumatol. 2025 Sep 1. doi: 10.1038/s41584-025-01291-0.

[Evidence and updated guidelines of the European Society for Blood and Marrow Transplantation on autologous hematopoietic stem cell transplantation in inflammatory rheumatic diseases].

Z Rheumatol. 2025 Aug 21. doi: 10.1007/s00393-025-01699-9.

Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02695-y.

Advances in the treatment of systemic lupus erythematosus.

Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0.

Immunotargets and Therapy for Systemic Lupus Erythematosus.

Immunotargets Ther. 2025 Jun 24;14:605-629. doi: 10.2147/ITT.S485650. eCollection 2025.

Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.

Cell Mol Biol Lett. 2025 Jun 16;30(1):73. doi: 10.1186/s11658-025-00749-z.

Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma.

EJHaem. 2025 May 25;6(3):e70062. doi: 10.1002/jha2.70062. eCollection 2025 Jun.

Insights from the 2024 pediatric rheumatology basic/translational years in review.

Pediatr Rheumatol Online J. 2025 May 23;23(1):57. doi: 10.1186/s12969-025-01102-6.

Fibroblasts in immune responses, inflammatory diseases and therapeutic implications.

Nat Rev Rheumatol. 2025 May 14. doi: 10.1038/s41584-025-01259-0.

BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.

Nat Med. 2025 Apr 17. doi: 10.1038/s41591-025-03718-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验